Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

AIM ImmunoTech stock

AIM
US00901B1052
A2PREX

Price

0.24
Today +/-
-0.00
Today %
-0.25 %
P

AIM ImmunoTech stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the AIM ImmunoTech stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the AIM ImmunoTech stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the AIM ImmunoTech stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze AIM ImmunoTech's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

AIM ImmunoTech Stock Price History

DateAIM ImmunoTech Price
11/8/20240.24 undefined
11/7/20240.24 undefined
11/6/20240.25 undefined
11/5/20240.25 undefined
11/4/20240.26 undefined
11/1/20240.26 undefined
10/31/20240.26 undefined
10/30/20240.25 undefined
10/29/20240.27 undefined
10/28/20240.27 undefined
10/25/20240.27 undefined
10/24/20240.26 undefined
10/23/20240.26 undefined
10/22/20240.27 undefined
10/21/20240.26 undefined
10/18/20240.25 undefined
10/17/20240.26 undefined
10/16/20240.26 undefined
10/15/20240.26 undefined
10/14/20240.26 undefined

AIM ImmunoTech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into AIM ImmunoTech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AIM ImmunoTech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AIM ImmunoTech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of AIM ImmunoTech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into AIM ImmunoTech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing AIM ImmunoTech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AIM ImmunoTech’s growth potential.

AIM ImmunoTech Revenue, EBIT and net profit per share

DateAIM ImmunoTech RevenueAIM ImmunoTech EBITAIM ImmunoTech Net Income
2029e118.27 M undefined156.89 M undefined37.73 M undefined
2028e51.55 M undefined-12 M undefined-11.51 M undefined
2027e9.85 M undefined-42.53 M undefined-40.29 M undefined
2026e3.86 M undefined-22.58 M undefined-29.1 M undefined
2025e1.8 M undefined-20.03 M undefined-26.22 M undefined
2024e151,500 undefined-20.6 M undefined-21.53 M undefined
2023202,000 undefined-31.92 M undefined-28.96 M undefined
2022141,000 undefined-19.92 M undefined-19.45 M undefined
2021135,000 undefined-17.06 M undefined-19.13 M undefined
2020163,000 undefined-15.02 M undefined-14.4 M undefined
2019140,000 undefined-12.44 M undefined-9.4 M undefined
2018367,000 undefined-11.5 M undefined-9.81 M undefined
2017437,000 undefined-11.42 M undefined-8.26 M undefined
201692,000 undefined-13.8 M undefined-7.5 M undefined
2015133,000 undefined-16.65 M undefined-15.23 M undefined
2014197,000 undefined-19.1 M undefined-17.45 M undefined
2013150,000 undefined-17.17 M undefined-16.23 M undefined
2012210,000 undefined-20.34 M undefined-17.35 M undefined
2011160,000 undefined-14.3 M undefined-9.02 M undefined
2010140,000 undefined-16.39 M undefined-13.14 M undefined
2009110,000 undefined-13.26 M undefined-7.18 M undefined
2008270,000 undefined-12.81 M undefined-12.22 M undefined
20071.06 M undefined-19.29 M undefined-18.14 M undefined
2006930,000 undefined-18.69 M undefined-19.4 M undefined
20051.08 M undefined-9.92 M undefined-12.45 M undefined
20041.23 M undefined-10.89 M undefined-24.14 M undefined

AIM ImmunoTech Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000020000000011010000000000000000013951118
-----------------------------------200.00200.00466.67131.37
---------------------------------------
0000000000000000000-10-1-1-1-1-10000000000000
-8-7-5-40-4-5-7-9-9-8-6-7-10-9-18-19-12-13-16-14-20-17-19-16-13-11-11-12-15-17-19-31-20-20-22-42-11156
--------------1,000.00-900.00--1,900.00------------------2,000.00-733.33-466.67-21.57132.20
-8-7-7-5-1-4-6-7-9-8-9-7-14-24-12-19-18-12-7-13-9-17-16-17-15-7-8-9-9-14-19-19-28-21-26-29-40-1137
--12.50--28.57-80.00300.0050.0016.6728.57-11.1112.50-22.22100.0071.43-50.0058.33-5.26-33.33-41.6785.71-30.7788.89-5.886.25-11.76-53.3314.2912.50-55.5635.71-47.37-25.0023.8111.5437.93-72.50-436.36
0.020.020.020.020.020.030.030.040.050.060.060.060.070.090.10.120.140.140.210.250.260.270.320.360.450.50.6513.6431.8447.3448.0548.59000000
---------------------------------------
Details

Keystats

Revenue and Growth

The AIM ImmunoTech Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the AIM ImmunoTech is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                           
0.0611.295.289.9713.628.558.388.422.815.2616.7416.222.0215.426.1258.0735.6130.3643.9518.1916.118.915.872.111.838.783948.2734.1913.07
0000.030.060.080.060.011.510.280.140.10.090.080000000000.021.090.821.121.641.681.18
000002.25000000000000000000000000
0000000002.92.151.770.960.510.8600.790.90.45001.3300000000
00.060.110.070.060.140.610.380.070.170.270.140.170.60.330.330.280.530.320.360.40.341.071.370.880.850.180.30.460.3
0.0611.355.3910.0713.7411.029.058.814.398.6119.318.2123.2416.617.3158.436.6831.7944.7218.5516.5110.576.943.513.810.4540.3150.2136.3214.56
0.10.050.080.070.180.330.370.250.160.093.34.195.345.294.884.845.366.7611.8712.111.9411.249.518.597.787.276.654.21.020.82
00001.041.412.421.880.410.410.040.040.040.040.040.048.814.030000000015.38000
0000000001.31.31.31.300000000000000000
1.431.251.51.391.361.361.21.0311.030.910.80.860.960.970.830.790.861.031.080.860.860.870.860.911.151.51.971.942.31
000000000000000000000000000000
0.050.050.030.020.020.040.020.080.091.970.340.130.660.260.020.890.040.070.070.140.130.131.551.261.351.890.751.321.21.69
1.581.351.611.482.63.144.013.241.664.85.896.468.26.555.916.61511.7212.9713.3212.9312.2311.9310.710.0510.3124.277.494.174.83
1.6412.7711.5516.3414.1613.0612.056.0513.4125.1924.6731.4423.1613.226551.6843.5157.6931.8729.4422.818.8714.2113.8520.7564.5857.740.4919.38
                                                           
16.280.020.020.020.030.030.030.030.030.040.050.060.070.070.080.130.140.140.170.170.20.250.020.030.050.790.770.760.740.74
14.0447.9554.0865.2678.0684.8897.98106.83107.16123.05158.02166.39191.69206.08208.87263.15264.51264.96288.67289.56302.73313.22315.98317.42323.7340.23402.54417.22418.27419
-41.7-43.54-48.24-54.39-61.72-70.92-82.57-91.65-99.07-113.84-137.98-147.65-167.05-185.19-197.41-204.59-217.73-226.74-244.09-260.32-277.77-293-300.5-308.76-318.57-327.57-341.97-361.1-380.55-409.51
000-140-1,190-3103020400-10-17050-100000000000000000
0000000000000000-970-390-40-110-160-97-511-30-47000
-11.384.435.8610.7515.1813.6815.4715.238.169.2520.0818.6324.7620.9511.5458.6945.9537.9744.7129.32520.3715.58.75.1713.4461.2956.8838.4710.23
2.251.10.60.470.81.091.340.980.790.490.530.991.551.120.791.291.331.682.161.272.081.210.890.740.680.470.380.20.386.44
2.31.770.290.260.250.360.150.290.681.121.010.871.260.780.741.211.331.533.281.232.331.221.551.971.010.440.490.480.982.21
0490260809060000000029013011011011011000000000000
8.474.920000000000000001.77.05000003.4100000
0.020000000003.2503.870000.060.050.050.0300000.20.210.23000
13.048.281.150.811.141.511.491.271.471.614.791.866.682.191.662.612.835.0712.652.534.412.432.442.715.291.131.10.671.368.65
0000000002.060.314.1700000.10.10.060.020001.842.326.011.88000
000000000000000000000000000000
0000000000.49000003.682.810.380.30.01000.940.961.060.170.310.150.660.5
0000000002.550.314.170003.682.910.480.360.03000.942.83.386.192.190.150.660.5
13.048.281.150.811.141.511.491.271.474.165.16.036.682.191.666.295.745.5513.012.564.412.433.385.58.677.313.290.822.029.15
1.6612.717.0111.5616.3215.1916.9616.59.6313.4125.1824.6631.4423.1413.264.9851.6943.5257.7231.8629.4222.818.8714.2113.8520.7564.5857.740.4919.38
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of AIM ImmunoTech provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand AIM ImmunoTech's financial health and stability.

Assets

AIM ImmunoTech's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that AIM ImmunoTech must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of AIM ImmunoTech after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into AIM ImmunoTech's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-7-5-1-4-6-7-9-8-9-7-14-24-12-19-18-12-7-13-9-17-16-17-15-7-8-9-9-14-19-19-28
0000000000000000000001,0001,0001,0001,000000000
0000000000000000000000000000000
020-20000000111012002-21-201-200007
10001010117153330-50-11100-1-1002320
0000000000000000000000000000000
0000000000000000000000000000000
-5-1-1-6-4-5-6-8-7-6-7-7-7-13-15-9-9-11-10-13-16-13-16-7-7-10-9-10-13-16-21
0000000000000-1000-1-2-5-10000000000
0000-1-2-1-304-1-6-5-71330-438-162226220-6-90100
0000-1-10-204-1-6-5-51430-4210-102336320-5-80110
0000000000000000000000000000000
20-2-400000011700-4000150000141-4-400
011859112870112820110610023012942515611300
321309102870101982080610128-61294491656800
00-2,0000000000-2,0000001,00000000-7,0000000000000
0000000000000000000000000000000
-2011-633-5-20015-407-551-5500-11000-1137-6-5-21
-5.57-2.34-2.08-6.58-4.96-6.28-7.47-8.44-7.5-6.59-7.19-7.6-7.57-15.17-15.53-9.58-9.87-12.96-12.14-19.11-17.97-14.73-16.54-7.83-8.01-10.77-9.43-10.96-14.6-16.38-21.85
0000000000000000000000000000000

AIM ImmunoTech stock margins

The AIM ImmunoTech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AIM ImmunoTech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AIM ImmunoTech.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the AIM ImmunoTech's sales revenue. A higher gross margin percentage indicates that the AIM ImmunoTech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the AIM ImmunoTech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the AIM ImmunoTech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AIM ImmunoTech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AIM ImmunoTech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AIM ImmunoTech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

AIM ImmunoTech Margin History

AIM ImmunoTech Gross marginAIM ImmunoTech Profit marginAIM ImmunoTech EBIT marginAIM ImmunoTech Profit margin
2029e79.21 %132.65 %31.9 %
2028e79.21 %-23.28 %-22.33 %
2027e79.21 %-431.88 %-409.12 %
2026e79.21 %-585.37 %-754.24 %
2025e79.21 %-1,113.92 %-1,458.33 %
2024e79.21 %-13,600 %-14,211.96 %
202379.21 %-15,800 %-14,337.62 %
2022100 %-14,129.79 %-13,790.78 %
2021-529.63 %-12,636.3 %-14,168.15 %
2020-394.48 %-9,212.88 %-8,834.36 %
2019-537.86 %-8,887.86 %-6,717.14 %
2018-140.87 %-3,132.43 %-2,673.84 %
2017-170.71 %-2,612.36 %-1,889.93 %
2016-1,104.35 %-15,004.35 %-8,154.35 %
2015-1,101.5 %-12,518.8 %-11,451.13 %
2014-535.03 %-9,694.92 %-8,857.87 %
2013-720 %-11,446.67 %-10,820 %
2012-847.62 %-9,685.72 %-8,261.91 %
2011-550 %-8,937.5 %-5,637.5 %
2010-864.29 %-11,707.14 %-9,385.72 %
2009-427.27 %-12,054.55 %-6,527.27 %
2008-196.3 %-4,744.44 %-4,525.93 %
200712.26 %-1,819.81 %-1,711.32 %
2006-36.56 %-2,009.68 %-2,086.02 %
200563.89 %-918.52 %-1,152.78 %
2004-71.54 %-885.37 %-1,962.6 %

AIM ImmunoTech Stock Sales Revenue, EBIT, Earnings per Share

The AIM ImmunoTech earnings per share therefore indicates how much revenue AIM ImmunoTech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue AIM ImmunoTech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AIM ImmunoTech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AIM ImmunoTech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AIM ImmunoTech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AIM ImmunoTech Revenue, EBIT and net profit per share

DateAIM ImmunoTech Sales per ShareAIM ImmunoTech EBIT per shareAIM ImmunoTech Earnings per Share
2029e1.87 undefined0 undefined0.6 undefined
2028e0.81 undefined0 undefined-0.18 undefined
2027e0.16 undefined0 undefined-0.64 undefined
2026e0.06 undefined0 undefined-0.46 undefined
2025e0.03 undefined0 undefined-0.41 undefined
2024e0 undefined0 undefined-0.34 undefined
20230 undefined-0.66 undefined-0.6 undefined
20220 undefined-0.41 undefined-0.4 undefined
20210 undefined-0.36 undefined-0.4 undefined
20200.01 undefined-0.47 undefined-0.45 undefined
20190.04 undefined-3.42 undefined-2.58 undefined
20180.37 undefined-11.45 undefined-9.77 undefined
20170.67 undefined-17.52 undefined-12.67 undefined
20160.19 undefined-27.84 undefined-15.13 undefined
20150.3 undefined-37.23 undefined-34.05 undefined
20140.55 undefined-53.55 undefined-48.93 undefined
20130.47 undefined-53.66 undefined-50.72 undefined
20120.78 undefined-75.33 undefined-64.26 undefined
20110.62 undefined-55 undefined-34.69 undefined
20100.56 undefined-65.56 undefined-52.56 undefined
20090.52 undefined-63.14 undefined-34.19 undefined
20081.93 undefined-91.5 undefined-87.29 undefined
20077.57 undefined-137.79 undefined-129.57 undefined
20067.75 undefined-155.75 undefined-161.67 undefined
200510.8 undefined-99.2 undefined-124.5 undefined
200413.67 undefined-121 undefined-268.22 undefined

AIM ImmunoTech business model

AIM ImmunoTech Inc is a US-based biotechnology company that focuses on the development of immunotherapeutics and diagnostics for humans and animals. The company has been in operation for over 30 years and specializes in the treatment of viral and autoimmune diseases. AIM ImmunoTech is one of the most popular companies on Eulerpool.com.

AIM ImmunoTech SWOT Analysis

Strengths

AIM ImmunoTech Inc has a strong portfolio of drugs and therapies that are focused on enhancing the immune system and treating a wide range of diseases.

The company's flagship product Ampligen has shown potential in clinical trials as an effective treatment for Chronic Fatigue Syndrome (CFS) and has received orphan drug designation from the FDA.

AIM ImmunoTech Inc has a dedicated and experienced research and development team that is continually working on improving existing products and developing new ones.

Weaknesses

The company heavily relies on government grants, contracts, and partnerships for funding its research and development activities. Any reduction or loss of these funding sources may impact the company's ability to progress with its projects.

AIM ImmunoTech Inc faces significant competition from other biotech companies in the field of immune system therapies. This competitive landscape may pose challenges in gaining market share and generating sustainable revenue.

The regulatory approval process for new drugs and therapies is complex and time-consuming. Delays or rejections in obtaining necessary approvals may hinder the company's growth and commercialization efforts.

Opportunities

The growing focus on immunotherapies and the increasing prevalence of diseases such as cancer and viral infections provide a significant market opportunity for AIM ImmunoTech Inc to expand its product offerings and reach a larger patient population.

The company can leverage its existing expertise in immune system enhancement to explore partnerships and collaborations with pharmaceutical companies for the development of combination therapies.

Advancements in technology and research in the field of immunology offer the potential for AIM ImmunoTech Inc to develop innovative and more targeted treatments, further enhancing its competitive position.

Threats

Changes in government policies and regulations related to healthcare and drug development may impact the funding and market access for AIM ImmunoTech Inc's products.

The uncertainty of the clinical trial process and unpredictable outcomes may pose financial risks and setbacks for the company.

Increasing competition from established pharmaceutical companies and the emergence of new players in the immuno-oncology and immunotherapy markets can pose a threat to AIM ImmunoTech Inc's market share and revenue growth.

AIM ImmunoTech Revenue by Segment

  • Max

Details

Revenue by Segment

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

AIM ImmunoTech Revenue by Segment

Segmente2021
Clinical Treatment Programs U S135,000 USD

AIM ImmunoTech Revenue by Region

  • 3 years

  • Max

Details

Revenue by Segment

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

AIM ImmunoTech Revenue by Segment

DateEuropeUnited States
202019,000 USD144,000 USD

AIM ImmunoTech Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

AIM ImmunoTech historical P/E ratio, EBIT multiple, and P/S ratio

AIM ImmunoTech shares outstanding

The number of shares was AIM ImmunoTech in 2023 — This indicates how many shares 48.585 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue AIM ImmunoTech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates AIM ImmunoTech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of AIM ImmunoTech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating AIM ImmunoTech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

AIM ImmunoTech stock splits

In AIM ImmunoTech's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for AIM ImmunoTech.

AIM ImmunoTech latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.12 -0.04  (67.9 %)2024 Q2
3/31/2024-0.12 -0.12  (-3.27 %)2024 Q1
12/31/2023-0.15 -0.26  (-71.62 %)2023 Q4
9/30/2023-0.11 -0.16  (-44.01 %)2023 Q3
6/30/2023-0.11 -0.1  (9.99 %)2023 Q2
3/31/2023-0.11 -0.08  (27.99 %)2023 Q1
12/31/2022-0.12 -0.09  (25.74 %)2022 Q4
9/30/2022-0.09 -0.13  (-51.34 %)2022 Q3
6/30/2022-0.08 -0.1  (-31.93 %)2022 Q2
3/31/2022-0.07 -0.08  (-13.15 %)2022 Q1
1
2
3
4

AIM ImmunoTech shareholders

%
Name
Stocks
Change
Date
6.44030 % Armistice Capital LLC4,078,0004,078,0006/30/2024
3.14072 % The Vanguard Group, Inc.1,988,70406/30/2024
2.71020 % Deutsch (Todd A)1,716,10009/11/2024
2.35793 % Equels (Thomas K)1,493,042337,5009/16/2024
2.35786 % Kellner (Ted D)1,493,00009/11/2024
1.10276 % BlackRock Institutional Trust Company, N.A.698,267-666/30/2024
0.63370 % Rodino (Peter W III)401,262188,6798/12/2024
0.63333 % Geode Capital Management, L.L.C.401,02749,3706/30/2024
0.37866 % Appelrouth (Stewart L.)239,76590,9103/24/2024
0.36135 % Renaissance Technologies LLC228,8088,0006/30/2024
1
2
3
4
5
...
8

AIM ImmunoTech Executives and Management Board

Mr. Thomas Equels(70)
AIM ImmunoTech President, Chief Executive Officer, Executive Vice Chairman (since 2008)
Compensation 1.35 M
Mr. Peter Rodino(71)
AIM ImmunoTech Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Secretary (since 2013)
Compensation 699,298
Dr. David Strayer(76)
AIM ImmunoTech Chief Scientific and Medical Officer
Compensation 314,340
Dr. William Mitchell(88)
AIM ImmunoTech Independent Chairman of the Board
Compensation 233,165
Mr. Stewart Appelrouth(69)
AIM ImmunoTech Independent Director
Compensation 233,165
1
2

Most common questions regarding AIM ImmunoTech

What values and corporate philosophy does AIM ImmunoTech represent?

AIM ImmunoTech Inc represents values of innovation, dedication, and patient-centricity. The company's corporate philosophy is centered around developing novel, cutting-edge immunotherapies that address unmet medical needs. AIM ImmunoTech Inc is committed to enhancing patient outcomes by harnessing the power of the immune system to target diseases such as cancer, viral infections, and immune disorders. Through rigorous research and clinical trials, the company continually strives to improve the quality of life for patients worldwide. AIM ImmunoTech Inc's mission is to provide effective and safe therapies that revolutionize the treatment landscape, offering hope and improved health outcomes for individuals facing these challenging conditions.

In which countries and regions is AIM ImmunoTech primarily present?

AIM ImmunoTech Inc is primarily present in the United States of America (USA).

What significant milestones has the company AIM ImmunoTech achieved?

AIM ImmunoTech Inc. has achieved several significant milestones in its journey. The company has made notable strides in the field of immune system-based technologies and therapies. They successfully developed and gained regulatory approval for various products, including Ampligen® and Alferon N Injection®, which have shown promising results in the treatment of different diseases. AIM ImmunoTech Inc. has also established partnerships and collaborations with renowned research organizations, facilitating advancements in the medical community. Additionally, the company has made noteworthy progress in clinical trials, expanding its understanding of the therapeutic potential of its products. These milestones highlight AIM ImmunoTech Inc.'s commitment to advancing innovative solutions in the biomedical field.

What is the history and background of the company AIM ImmunoTech?

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida. Founded in 1966, AIM ImmunoTech specializes in the development and commercialization of immunotherapy-based treatments for various medical conditions. The company focuses on harnessing the power of the immune system to fight diseases such as cancer, viral infections, and autoimmune disorders. AIM ImmunoTech is well-known for its drug Ampligen, which has shown promise in treating chronic fatigue syndrome and certain types of cancers. With a rich history spanning over 50 years, AIM ImmunoTech is dedicated to advancing innovative therapies to improve patients' lives.

Who are the main competitors of AIM ImmunoTech in the market?

Some of the main competitors of AIM ImmunoTech Inc in the market include companies like Bristol-Myers Squibb, Merck & Co., and Novartis. These pharmaceutical giants also focus on developing and commercializing innovative immunotherapies and pharmaceutical products. AIM ImmunoTech Inc faces competition in the areas of drug research and development, clinical trials, market penetration, and product adoption. Despite this competitive landscape, AIM ImmunoTech Inc strives to differentiate itself through its unique approach to immunotherapy and the development of potential treatments for diseases such as cancer and viral infections.

In which industries is AIM ImmunoTech primarily active?

AIM ImmunoTech Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of AIM ImmunoTech?

AIM ImmunoTech Inc is a biopharmaceutical company focused on developing and commercializing immunotherapy products for the treatment of multiple diseases. Their business model revolves around the development of novel therapeutics and immune system stimulants to address significant unmet medical needs. AIM ImmunoTech Inc aims to leverage their expertise in immune system modulation to develop innovative treatments that can potentially improve patient outcomes. Through their research and development efforts, they strive to introduce effective and safe immunotherapies that may offer new hope for patients suffering from various diseases.

What is the P/E ratio of AIM ImmunoTech 2024?

The AIM ImmunoTech P/E ratio is -0.55.

What is the P/S ratio of AIM ImmunoTech 2024?

The AIM ImmunoTech P/S ratio is 78.25.

What is the Quality Investing of AIM ImmunoTech?

The Quality Investing for AIM ImmunoTech is 5/10.

What is the revenue of AIM ImmunoTech 2024?

The expected AIM ImmunoTech revenue is 151,500 USD.

How high is the profit of AIM ImmunoTech 2024?

The expected AIM ImmunoTech profit is -21.53 M USD.

What is the business model of AIM ImmunoTech

AIM ImmunoTech Inc is a biotechnology company that focuses on developing immunotherapies for the treatment of serious diseases such as cancer and infectious diseases. The company is a pioneer in the field of immune stimulants, which stimulate the body's immune system to intervene in cancer cells and infected cells. The company operates in two main business areas - oncology and infectious diseases. In the oncology business, AIM ImmunoTech focuses on developing immune stimulants as adjuncts to chemotherapy and radiation in the fight against cancer. AIM ImmunoTech's flagship immunotherapy is Ampligen®, an immune stimulant that has shown potential as a cancer immunotherapy and is frequently used in clinical studies in cancer patients. The company also intends to further develop its immunotherapy candidates to improve their effectiveness. In the field of infectious diseases, AIM ImmunoTech Inc focuses on antiviral and antibacterial therapeutic solutions. Given the current COVID-19 pandemic, the company has received particular attention as Ampligen® has shown promising results in improving the immune systems of COVID-19 patients. The company is also working on the development of antiviral and antimicrobial agents to combat infections such as herpes simplex viruses, Ebola virus, and Rift Valley fever. In addition to developing immune stimulants as immunotherapy candidates, AIM ImmunoTech also operates business units such as the sales and marketing of ImmuBoost®, a dietary supplement containing natural immune boosters. Furthermore, the company has planned the development of products in close cooperation with life science companies such as Shandong Buchang Pharmaceutica and Yangtze River Pharmaceutical. AIM ImmunoTech Inc also collaborates closely with academic institutions and individuals to expand the scientific understanding of different diseases and their treatment. The company is proud to be a central component in the fight against cancer and infectious diseases and hopes to soon present an important addition to the medical portfolio. Overall, AIM ImmunoTech Inc takes a multidimensional approach to immunotherapy product development and marketing and operates a wide range of business areas. The company is committed to continuously strengthening its business model and expanding its position as a tireless innovator and leader in the biotechnology industry.

What is the AIM ImmunoTech dividend?

AIM ImmunoTech pays a dividend of 0 USD distributed over payouts per year.

How often does AIM ImmunoTech pay dividends?

The dividend cannot currently be calculated for AIM ImmunoTech or the company does not pay out a dividend.

What is the AIM ImmunoTech ISIN?

The ISIN of AIM ImmunoTech is US00901B1052.

What is the AIM ImmunoTech WKN?

The WKN of AIM ImmunoTech is A2PREX.

What is the AIM ImmunoTech ticker?

The ticker of AIM ImmunoTech is AIM.

How much dividend does AIM ImmunoTech pay?

Over the past 12 months, AIM ImmunoTech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AIM ImmunoTech is expected to pay a dividend of 0 USD.

What is the dividend yield of AIM ImmunoTech?

The current dividend yield of AIM ImmunoTech is .

When does AIM ImmunoTech pay dividends?

AIM ImmunoTech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AIM ImmunoTech?

AIM ImmunoTech paid dividends every year for the past 0 years.

What is the dividend of AIM ImmunoTech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is AIM ImmunoTech located?

AIM ImmunoTech is assigned to the 'Health' sector.

Wann musste ich die Aktien von AIM ImmunoTech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AIM ImmunoTech from 11/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/10/2024.

When did AIM ImmunoTech pay the last dividend?

The last dividend was paid out on 11/10/2024.

What was the dividend of AIM ImmunoTech in the year 2023?

In the year 2023, AIM ImmunoTech distributed 0 USD as dividends.

In which currency does AIM ImmunoTech pay out the dividend?

The dividends of AIM ImmunoTech are distributed in USD.

All fundamentals about AIM ImmunoTech

Our stock analysis for AIM ImmunoTech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AIM ImmunoTech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.